← boothcheck

Is MET overvalued?

boothcheck doesn't label MET overvalued or undervalued, and it doesn't publish a fair value. It shows what the price assumes instead. At today's price, MET is priced for growth of +17.5% sustained for about 20 years. The price is justified by relative-multiple and growth-DCF; earnings-power land below the price. The more the price assumes beyond what MetLife, Inc. has actually delivered, the more has to go right to justify it. Whether that bar is too high is your call, and the full bull and bear cases are in the report.

Derived from MetLife, Inc.'s SEC EDGAR filings via a reverse-DCF inversion. Last analyzed June 27, 2026.

Implied growth+17.5%
For about20 yrs
Margin needed
Margin today
Price vs asset value1.34x
Price vs earnings power1.66x
Price vs peer multiples0.90x
Price vs forward growth1.24x
Read the full MET report →
Get boothcheck's read on what MET's price is betting on, in your inbox when it moves. No hype, no spam.
Free. Informational only, not investment advice. Unsubscribe anytime.

For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.